Эффекты коррекции дефицита железа у пациентов с сердечной недостаточностью различной этиологии и сопутствующими заболеваниями

Дефицит железа (ДЖ) у пациентов с сердечной недостаточностью (СН) является фактором неблагоприятного течения заболевания и прогноза. Значение ДЖ в диагностике и лечении пациентов с СН ранее продемонстрировано в большом количестве исследований и метаанализов. Терапия ДЖ у пациентов с СН - один из самых актуальных и обсуждаемых вопросов. Применение препаратов железа для внутривенного введения в целях лечения ДЖ в настоящее время активно изучается у пациентов различных категорий, осуществляются попытки уточнения показаний к применению с целью получения наибольшего влияния на прогноз и качество жизни пациентов с СН.

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–39. DOI: 10.1093/eurheartj/ehad195

2. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018;138(1):80–98. DOI: 10.1161/CIRCULATIONAHA.118.030099

3. Klip IjT, Comin­Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W et al. Iron deficiency in chronic heart failure: An international pooled analysis. American Heart Journal. 2013;165(4):575­582.e3. DOI: 10.1016/j.ahj.2013.01.017

4. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal. 2010;31(15):1872–80. DOI: 10.1093/eurheartj/ehq158

5. Rocha BML, Cunha GJL, Menezes Falcão LF. The Burden of Iron Deficiency in Heart Failure. Journal of the American College of Cardiology. 2018;71(7):782–93. DOI: 10.1016/j.jacc.2017.12.027

6. Cohen­Solal A, Damy T, Terbah M, Kerebel S, Baguet J­P, Hanon O et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. European Journal of Heart Failure. 2014;16(9):984–91. DOI: 10.1002/ejhf.139

7. von Haehling S, Gremmler U, Krumm M, Mibach F, Schön N, Taggeselle J et al. Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clinical Research in Cardiology. 2017;106(6):436–43. DOI: 10.1007/s00392­016­1073­y

8. Alnuwaysir RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, Gomez KA, Van Der Wal HH et al. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. European Journal of Heart Failure. 2022;24(1):192–204. DOI: 10.1002/ejhf.2393

9. Fitzsimons S, Yeo TJ, Ling LH, Sim D, Leong KTG, Yeo PSD et al. Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. ESC Heart Failure. 2021;8(6):4572–83. DOI: 10.1002/ehf2.13617

10. Enjuanes C, Klip IjT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W et al. Iron deficiency and health­related quality of life in chronic heart failure: Results from a multicenter European study. International Journal of Cardiology. 2014;174(2):268–75. DOI: 10.1016/j.ijcard.2014.03.169

11. Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid­range and preserved ejection fraction. Acta Cardiologica. 2018;73(2):115–23. DOI: 10.1080/00015385.2017.1351239

12. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Ole kowska­Florek W et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. European Heart Journal. 2014;35(36):2468–76. DOI: 10.1093/eurheartj/ehu235

13. Nakano H, Nagai T, Sundaram V, Nakai M, Nishimura K, Honda Y et al. Impact of iron deficiency on long­term clinical outcomes of hospitalized patients with heart failure. International Journal of Cardiology. 2018;261:114–8. DOI: 10.1016/j.ijcard.2018.03.039

14. Van Der Wal HH, Grote Beverborg N, Dickstein K, Anker SD, Lang CC, Ng LL et al. Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. European Heart Journal. 2019;40(44):3616–25. DOI: 10.1093/eurheartj/ehz680

15. Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency FERRIC­HF: a randomized, controlled, observer­blinded trial. Journal of the American College of Cardiology. 2008;51(2):103–12. DOI: 10.1016/j.jacc.2007.09.036

16. Ponikowski P, van Veldhuisen DJ, Comin­Colet J, Ertl G, Komajda M, Mareev V et al. Beneficial effects of long­term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 2015;36(11):657–68. DOI: 10.1093/eurheartj/ehu385

17. Ponikowski P, Kirwan B­A, Anker SD, McDonagh T, Dorobantu M, Drozdz J et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double­blind, randomised, controlled trial. The Lancet. 2020;396(10266):1895–904. DOI: 10.1016/S0140­6736(20)32339­4

18. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA et al. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. New England Journal of Medicine. 2023;389(11):975–86. DOI: 10.1056/NEJMoa2304968

19. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, Van Veldhuisen DJ et al. Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta­analysis. European Heart Journal. 2023;ehad586. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehad586

20. Sama IE, Woolley RJ, Nauta JF, Romaine SPR, Tromp J, Ter Maaten JM et al. A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. European Journal of Heart Failure. 2020;22(5):821–33. DOI: 10.1002/ejhf.1811

21. Severino P, D’Amato A, Pucci M, Infusino F, Birtolo LI, Mariani MV et al. Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels. International Journal of Molecular Sciences. 2020;21(9):3167. DOI: 10.3390/ijms21093167

22. Metra M, Jankowska EA, Pagnesi M, Anker SD, Butler J, Dorigotti F et al. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial. European Journal of Heart Failure. 2022;24(10):1928–39. DOI: 10.1002/ejhf.2630

23. Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M et al. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure. 2022;24(1):143–68. DOI: 10.1002/ejhf.2351

24. Gajanana D, Shah M, Junpapart P, Romero­Corral A, Figueredo VM, Bozorgnia B. Mortality in systolic heart failure revisited: Ischemic versus non­ischemic cardiomyopathy. International Journal of Cardiology. 2016;224:15–7. DOI: 10.1016/j.ijcard.2016.08.316

25. Silverdal J, Sjöland H, Bollano E, Pivodic A, Dahlström U, Fu M. Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure. ESC Heart Failure. 2020;7(1):265–74. DOI: 10.1002/ehf2.12568

26. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circulation: Heart Failure. 2017;10(6):e003875. DOI: 10.1161/CIRCHEARTFAILURE.117.003875

27. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2009;361(25):2436–48. DOI: 10.1056/NEJMoa0908355

28. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. The American Journal of Cardiology. 2010;105(3):373–7. DOI: 10.1016/j.amjcard.2009.09.041

29. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I­Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135(8):724–35. DOI: 10.1161/CIRCULATIONAHA.116.024593

30. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM et al. In­hospital and 1­year mortality associated with diabetes in patients with acute heart failure: results from the ESC­HFA Heart Failure Long­Term Registry. European Journal of Heart Failure. 2017;19(1):54–65. DOI: 10.1002/ejhf.679

31. Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2018;20(5):853–72. DOI: 10.1002/ejhf.1170

32. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al. 2019 ESC Guidelines on diabetes, pre­diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020;41(2):255–323. DOI: 10.1093/eurheartj/ehz486

33. McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA et al. Heart Failure With Preserved Ejection Fraction and Diabetes. Journal of the American College of Cardiology. 2019;73(5):602–11. DOI: 10.1016/j.jacc.2018.11.033

34. Pavlović A, Polovina M, Ristić A, Seferović JP, Veljić I, Simeunović D et al. Long­term mortality is increased in patients with undetected prediabetes and type­2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. European Journal of Preventive Cardiology. 2019;26(1):72–82. DOI: 10.1177/2047487318807767

35. Coban E, Ozdogan M, Timuragaoglu A. Effect of Iron Deficiency Anemia on the Levels of Hemoglobin A1c in Nondiabetic Patients. Acta Haematologica. 2004;112(3):126–8. DOI: 10.1159/000079722

36. Kim C, Bullard KM, Herman WH, Beckles GL. Association Between Iron Deficiency and A1C Levels Among Adults Without Diabetes in the National Health and Nutrition Examination Survey, 1999–2006. Diabetes Care. 2010;33(4):780–5. DOI: 10.2337/dc09­0836

37. Ponikowska B, Suchocki T, Paleczny B, Olesinska M, Powierza S, Borodulin­Nadzieja L et al. Iron Status and Survival in Diabetic Patients With Coronary Artery Disease. Diabetes Care. 2013;36(12):4147–56. DOI: 10.2337/dc13­0528

38. Soliman AT, De Sanctis V, Yassin M, Soliman N. Iron deficiency anemia and glucose metabolism. Acta Bio Medica Atenei Parmensis. 2017;88(1):112–8. DOI: 10.23750/abm.v88i1.6049

39. Rosano G, Ponikowski P, Vitale C, Anker SD, Butler J, Fabien V et al. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM­AHF trial. Cardiovascular Diabetology. 2023;22(1):215. DOI: 10.1186/s12933­023­01943­z

40. Schindler C, Birkenfeld AL, Hanefeld M, Schatz U, Köhler C, Grüneberg M et al. Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol. Diabetes Therapy. 2018;9(1):37–47. DOI: 10.1007/s13300­017­0330­z

41. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, Di-Capua P et al. Renal impairment and outcomes in heart failure: systematic review and meta­analysis. Journal of the American College of Cardiology. 2006;47(10):1987–96. DOI: 10.1016/j.jacc.2005.11.084

42. Romero­González G, Ravassa S, González O, Lorenzo I, Rojas MA, García­Trigo I et al. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrología. 2020;40(3):223–36. DOI: 10.1016/j.nefro.2019.10.005

43. Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J et al. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. Journal of the American College of Cardiology. 2019;73(21):2691–700. DOI: 10.1016/j.jacc.2019.02.071

44. Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD et al. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology. 2021;78(4):330–43. DOI: 10.1016/j.jacc.2021.05.002

45. Wish JB, Anker SD, Butler J, Cases A, Stack AG, Macdougall IC. Iron Deficiency in CKD Without Concomitant Anemia. Kidney International Reports. 2021;6(11):2752–62. DOI: 10.1016/j.ekir.2021.07.032

46. Macdougall IC, Canaud B, De Francisco ALM, Filippatos G, Ponikowski P, Silverberg D et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. European Journal of Heart Failure. 2012;14(8):882–6. DOI: 10.1093/eurjhf/hfs056

47. Cunha GJL, Rocha BML, Menezes Falcão L. Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions. European Journal of Internal Medicine. 2018;52:1–7. DOI: 10.1016/j.ejim.2018.04.013

48. Macdougall IC, Ponikowski P, Stack AG, Wheeler DC, Anker SD, Butler J et al. Ferric Carboxymaltose in Iron­Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function. Clinical Journal of the American Society of Nephrology. 2023;18(9):1124–34. DOI: 10.2215/CJN.0000000000000223

49. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. New England Journal of Medicine. 2019;380(5):447–58. DOI: 10.1056/NEJMoa1810742

50. Xia H, Shen H, Cha W, Lu Q. The Prognostic Significance of Anemia in Patients With Heart Failure: A Meta­Analysis of Studies From the Last Decade. Frontiers in Cardiovascular Medicine. 2021;8:632318. DOI: 10.3389/fcvm.2021.632318

51. Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R et al. Intravenous ferric carboxymaltose in iron­deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR­HF trial. European Journal of Heart Failure. 2013;15(11):1267–76. DOI: 10.1093/eurjhf/hft099

52. Young JB, Anand IS, Diaz R, Maggioni AP, McMurray JJV, C. O et al. Reduction of Events with Darbepoetin alfa in Heart Failure (RED­HF)TM Trial. Journal of Cardiac Failure. 2006;12(6):S77. DOI: 10.1016/j.cardfail.2006.06.264

53. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine. 2013;368(13):1210–9. DOI: 10.1056/NEJMoa1214865

54. Filippatos G, Ponikowski P, Farmakis D, Anker SD, Butler J, Fabien V et al. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM­AHF Subgroup Analysis. Circulation. 2023;147(22):1640–53. DOI: 10.1161/CIRCULATIONAHA.122.060757

55. World Health Organisation. Hemoglobin concentration for the diagnosis of anemia and assessment of its severity. Vitamin and Mineral Nutrition Information System. Av. at: https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22.

56. Beavers CJ, Ambrosy AP, Butler J, Davidson BT, Gale SE, Piña IL et al. Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America. Journal of Cardiac Failure. 2023;29(7):1059–77. DOI: 10.1016/j.cardfail.2023.03.025